Frontotemporal Dementia - Market Insight, Epidemiology And Market Forecast - 2032

This ‘Frontotemporal Dementia-Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Frontotemporal dementia (FTD), historical and forecasted epidemiology as well as the Frontotemporal Dementia market trends in the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Frontotemporal Dementia market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Frontotemporal Dementia market size from 2019 to 2032. The Report also covers current Frontotemporal Dementia treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Frontotemporal Dementia Disease Understanding and Treatment Algorithm

Frontotemporal Dementia Overview

FTD is a term used to describe a group of neurocognitive disorders that encompass progressive dysfunction in executive functioning, behavior, and language. There are three types of frontotemporal disorders (FTD): behavioral variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), and movement disorders.

FTD occurs when brain cells in the frontal or temporal lobes die due to the build-up of abnormal proteins, leading to abnormal brain function, and more cell deaths result in brain atrophy. Many possible symptoms can result, including unusual behaviors, emotional problems, trouble communicating, difficulty with work, or difficulty with walking.

Frontotemporal Dementia Diagnosis

FTD can be hard to diagnose as it displays clinical symptoms that can be mistaken for other dementias or psychiatric disorders. The average time from symptom onset to accurate diagnosis is about 3.6 years. Diagnosis of FTD currently includes Imaging and blood or cerebrospinal fluid studies.

A ‘definite' diagnosis of FTD is still based on neuropathology confirmation postmortem. Diagnostic markers currently used for FTD include imaging and blood or cerebrospinal fluid studies. They may best serve a diagnostic role when used in a multimodal approach to achieve a ‘definite' diagnosis of FTD in the living patient as soon as possible.

Frontotemporal Dementia Treatment

The management of problematic behaviors in FTD with mainly sparse case reports and case series detailing their effectiveness lacks the study quality. The main purpose of nonpharmacological interventions - described below - is to prevent disruptive behaviors, provide symptom relief, and lessen caregiver distress.

Diet and lifestyle

• Regular driving assessment should be conducted. Poor judgment, gaze abnormalities, executive dysfunction, and motor difficulties may all affect safe driving

Pharmacologic treatment of cognitive symptoms

• In FTD and related disorders, donepezil, rivastigmine, and galantamine are the three most commonly used acetylcholinesterase. Although none were adequately powered, and only one study was placebo-controlled, results have been disappointing across the board

Frontotemporal Dementia Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Cases of Frontotemporal Dementia (FTD), Type-specific Diagnosed Prevalent Cases of Frontotemporal Dementia (FTD) and Gene-specific Diagnosed Prevalent Cases of Frontotemporal Dementia (FTD) in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Key Findings

• Total diagnosed prevalent cases of FTD in the 7MM was found to be 128,570 in 2021, which might increase by the end of 2032. These cases are expected to increase at a CAGR of 0.3% during study period (2019-2032).
• Among 7MM, the United States has the highest prevalent cases of FTD with 58,960 cases in 2021.
• On the basis of type-specific diagnosed prevalent cases of FTD, bvFTD accounted for highest number of cases in 2021 with 35,846 cases in the United States.
• Among the European countries, Germany had the highest diagnosed prevalent population of FTD with 14,856 cases, followed by the France with 11,983 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
• Japan accounted for 11,845 diagnosed prevalent cases of FTD in the year 2021 which are expected to decrease during the forecasted period (2022-2032).

Frontotemporal Dementia Epidemiology

The epidemiology segment also provides the Frontotemporal Dementia epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Frontotemporal Dementia Drug Chapters

The drug chapter segment of the Frontotemporal Dementia report encloses the detailed analysis of FTD marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the FTD clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

Emerging Drugs

AL001: Alector

It is monoclonal antibody designed to modulate progranulin, a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including FTD, Alzheimer's disease, and Parkinson's disease. Company has initiated phase III trial for FTD-GRN mutation and undergoing phase II trials for FTD-C9orf72 to test its safety and efficacy towards FTD.

PBFT02: Passage Bio

It is a gene therapy that utilizes an AAV1 viral vector to deliver a modified DNA encoding the granulin (GRN) gene to a patients cells. The company has an active IND from the FDA and approved CTAs in multiple countries, which allows them to proceed with multi-center, open-label, single-arm Phase I/II clinical trial of PBFT02 in patients with a diagnosis of early symptomatic FTD-GRN.

Products detail in the report…
List of products to be

Frontotemporal Dementia Market Outlook

Currently, there are no FDA, EMA or PMDA (Pharmaceuticals and Medical Devices Agency) approved disease-modifying therapies for the management of FTD. The current treatment strategies mainly rely upon the off-label use of medications for symptomatic management, and most therapies lack quality evidence from randomized, placebo-controlled clinical trials.

The FTD drugs market is categorized based on drug class such as Selective serotonin reuptake inhibitors (Citalopram, Fluoxetine), Antipsychotic Agents, Cholinesterase Inhibitors (donepezil, rivastigmine, and galantamine), NMDA receptor antagonists (Memantine), and Benzodiazepine Antianxiety Drugs.

Key Findings

• The market size of Frontotemporal Dementia in seven major markets was USD 92 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 16% for the study period (2019-2032)
• The expected launch of potential therapy may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Frontotemporal Dementia.
• Upcoming therapy such as AL001 has the potential to create a significant positive shift in the Frontotemporal Dementia market size.
• The United States accounts for the largest market size of Frontotemporal Dementia, in comparison to the EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.

The United States Market Outlook

This section provides the total Frontotemporal Dementia market size and market size by therapies in the United States.

The EU-5 Market Outlook

The total Frontotemporal Dementia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Frontotemporal Dementia market size and market size by therapies in Japan are provided.

Frontotemporal Dementia Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Frontotemporal Dementia market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Frontotemporal Dementia market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Frontotemporal Dementia Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages also analyze key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Frontotemporal Dementia emerging therapies.

Reimbursement Scenario in Frontotemporal Dementia
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitively and market Intelligence analysis of the Frontotemporal Dementia market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Frontotemporal Dementia, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
• Comprehensive insight has been provided into the Frontotemporal Dementia epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Frontotemporal Dementia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Frontotemporal Dementia market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Frontotemporal Dementia market.

Report Highlights

• The robust pipeline with novel MOA and oral ROA and increasing diagnosed prevalence will positively drive the Frontotemporal Dementia market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal Dementia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Frontotemporal Dementia. The launch of emerging therapies will significantly impact the Frontotemporal Dementia market.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Frontotemporal Dementia Report Insights

• Patient Population
• Therapeutic Approaches
• Frontotemporal Dementia Pipeline Analysis
• Frontotemporal Dementia Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Frontotemporal Dementia Report Key Strengths

• 11-Years Forecast
• The 7MM Coverage
• Frontotemporal Dementia Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Frontotemporal Dementia Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• SWOT analysis

Key Questions

Market Insights:

• What was the Frontotemporal Dementia market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Frontotemporal Dementia total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Frontotemporal Dementia market size during the forecast period (2022-2032)?
• At what CAGR, the Frontotemporal Dementia market is expected to grow at the 7MM level during the forecast period (2022-2032)?
• What would be the Frontotemporal Dementia market outlook across the 7MM during the forecast period (2022-2032)?
• What would be the Frontotemporal Dementia market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden, and unmet needs of Frontotemporal Dementia?
• What is the historical Frontotemporal Dementia patient pool in the United States, the EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Frontotemporal Dementia at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Frontotemporal Dementia?
• Out of the above-mentioned countries, which country would have the highest population of Frontotemporal Dementia during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Frontotemporal Dementia along with the approved therapy?
• What are the current treatment guidelines for the treatment of Frontotemporal Dementia in the US and Europe?
• What are the Frontotemporal Dementia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Frontotemporal Dementia?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Frontotemporal Dementia?
• What are the key collaborations (Industry-Industry, Industry-Academia), mergers and acquisitions, licensing activities related to the Frontotemporal Dementia therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Frontotemporal Dementia and their status?
• What are the key designations that have been granted for the emerging therapies for Frontotemporal Dementia?
• What are the 7MM historical and forecasted market of Frontotemporal Dementia?

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving Frontotemporal Dementia.
• To understand the future market competition in the Frontotemporal Dementia market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Frontotemporal Dementia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Frontotemporal Dementia market.
• To understand the future market competition in the Frontotemporal Dementia market.